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December 13/20, 2011:2696–702trastuzumab. The authors might consider providing a baseline
image before chemotherapy for comparison. The paper describes
baseline CMR, including T2-weighted imaging, in the Methods
section, but does not report results. Our own experience with
CMR imaging after trastuzumab therapy instead points to revers-
ibly impaired LV function without LGE lesions, corresponding to
previous findings in echocardiography (5). So far, the authors are
the first to report LGE lesions after trastuzumab; therefore,
confirmatory studies by other groups are required. CMR might
have the potential to visualize tissue changes after chemotherapy
independent from changes in LV function and thereby guiding
patient management.
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Clinical Risk Stratification
of Chemotherapy-Induced
Cardiac Dysfunction
I read with great interest the recent publication by Fallah-Rad et
al. (1) on chemotherapy-induced cardiac dysfunction. I applaud
the authors for this integrated research in cardio-oncology utilizing
a multi-imaging modality, including cardiovascular magnetic res-
onance as I advocated in a previous publication (2).
Despite the valuable insights into early diagnosis of chemotherapy-
induced cardiac dysfunction provided by this study, there remain a
few unanswered clinical questions. First, among the cohort with
trastuzumab-associated cardiac dysfunction, what was the contri-bution from coronary artery disease (CAD) or ischemic heart
disease? CAD has been identified as a risk factor for chemotherapy
(3); additionally, antimetabolite chemotherapy agents, such as
5-fluorouracil, may be associated with ischemic heart disease (4).
Second, what was the impact of antiplatelet therapy on the results?
Aspirin therapy, part of the primary cardiovascular prevention
armamentarium, may also be beneficial in cancer patients, includ-
ing those with thrombocytopenia (5). Third, what was the statin
utilization rate among this cohort of cancer patients and its
impact on study outcome? In an animal model, statin pre-
treatment with fluvastatin attenuated doxorubicin-induced car-
diotoxicity (6).
This study demonstrates the promise of combined biomarker
and multi-imaging tools for early diagnosis of chemotherapy-
induced cardiac dysfunction; however, clinical cardiovascular risk
stratification of the cancer patients and survivors on chemotherapy
remains to be fully elucidated.
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Early Identification of
Left Ventricular Dysfunction
Induced by Trastuzumab
Cardiac monitoring and managing of patients receiving antineo-
plastic therapy is an actual issue. We agree with the interesting
article by Fallah-Rad et al. (1): new, sensitive indexes of cardiac
function are needed to predict cardiac dysfunction before ejection
fraction (EF) is compromised. Normal hearts have enormous
recruitable contractile capacity, and to show a decrease in EF, the
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December 13/20, 2011:2696–702myocardium must have undergone enough damage to exceed its
ability to compensate. The authors conclude that both tissue
velocity and strain imaging could detect pre-clinical changes in
cardiac function, before EF decreases, in patients receiving adju-
vant trastuzumab. Notably, they found no change in plasma
biomarkers (troponin T, C-reactive protein, and brain natriuretic
peptide); troponin I (TnI) was not evaluated.
Recently, Cardinale et al. (2) identified a subgroup of
rastuzumab-treated patients who exhibited elevations in serum
nI, and who were more likely to develop cardiotoxicity and less
ikely to recover, even when treated for cardiac dysfunction: prior
se of anthracyclines was a significant risk factor; cumulative
nthracycline dose was significantly higher. Elevation of TnI,
bserved exclusively in patients with prior anthracycline exposure,
as also found in 7 patients prior to trastuzumab therapy, despite
ormal EF, suggesting ongoing anthracycline-mediated myocyte
amage that would have otherwise gone unrecognized (3). Thus, it
ppeared that TnI leak was not a “pure” marker of trastuzumab
ardiotoxicity. Rather, trastuzumab exerted a modulating effect on
he vulnerable myocyte, previously damaged by anthracyclines.
Also, in line with our preliminary data on speckle tracking
etection of early left ventricular (LV) dysfunction in mice
reated with anti-ErbB2 agents, with increased cardiac fibrosis
videnced by histology (4,5), Fallah-Rad et al. (1) show
vidence of subepicardial linear delayed enhancement in the
ateral wall of the LV in trastuzumab cardiomyopathy, with a
rogressive decline in LVEF, despite discontinuation of tras-
uzumab and initiation of heart failure therapy, suggesting that
he paradigm of reversibility of trastuzumab-induced cardiomy-
pathy needs to be re-evaluated.
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Reply
Breast cancer and cardiovascular disease are major public health
concerns worldwide. The 2 diseases are intricately linked as
treatment with established chemotherapeutic agents and monoclo-
nal antibodies, including doxorubicin and trastuzumab, may lead
to breast cancer remission, but alternatively, may also lead to
significant cardiotoxicity. In the emerging field of cardio-oncology,
early indices of left ventricular (LV) systolic dysfunction would be
useful for addressing the cardiac safety profile of trastuzumab,
potentially avoiding the detrimental effects of heart failure.
We recently evaluated the utility of cardiac biomarkers, tissue
Doppler imaging (TDI), and cardiac magnetic resonance imaging
(CMR) for predicting early LV systolic dysfunction in HER-2–
positive breast cancer patients treated with trastuzumab in the
adjuvant setting (1). Of the 10 (25%) women who developed
trastuzumab-induced cardiotoxicity (TIC), cardiac biomarkers includ-
ing troponin (Tn)T, C-reactive protein, and brain natriuretic peptide
did not predict early LV systolic dysfunction (1). As suggested by
Tocchetti et al. (2), our findings contrast with a previous study in
which troponin I was able to identify a subset of women at high risk
of doxorubicin- and trastuzumab-mediated cardiac dysfunction prior
to a decrease in left ventricular ejection fraction (LVEF). One
potential explanation for the difference is the frequent sampling of
TnI, both before and after each trastuzumab cycle, as in the study by
Cardinale et al. (3), which provides a more accurate assessment of
biomarker levels in this patient population.
As compared with cardiac biomarkers, echocardiography using
TDI was sensitive in detecting pre-clinical changes in LV systolic
dysfunction. We agree with Dr. Tocchetti and colleagues that a
number of both basic science and clinical studies have recently
confirmed the utility of TDI for the early identification of LV
systolic dysfunction in breast cancer patients receiving doxorubicin
and trastuzumab (2,4–7). Although both TDI and strain imaging
were able to detect pre-clinical changes in LV systolic dysfunction
in breast cancer patients, the decision to either continue or
withhold trastuzumab therapy requires further study.
CMR using delayed enhancement (DE) is the gold standard for
the noninvasive assessment of cardiac volumes, systolic function,
and degree of fibrosis. To address the comments by Drs. Was-
smuth and Schulz-Menger, all 10 women in our study had normal
CMR studies at baseline, with no evidence of DE of the LV
myocardium, prior to initiation of doxorubicin and trastuzumab.
At 1-year follow-up, there was mid-myocardial DE of the lateral
wall of the LV in each of the 10 women with TIC, with no
evidence of myocardial edema on T2 imaging (1). We agree with
Drs. Wassmuth and Schulz-Menger that confirmatory studies by
other groups are required and likely forthcoming. As there was no
evidence of subendocardial DE in our patient population, one can
assume that there was no significant obstructive coronary artery
disease as questioned by Dr. Ntim. Finally, in response to Ntim,
there was no use of antiplatelet or statin therapy in our patient
cohort. The identification of DE of the LV myocardium in breast
cancer patients challenges the paradigm of whether trastuzumab-
mediated cardiac dysfunction is truly reversible in all cases.
The anticipated goal of cardio-oncologists should be to continue to
improve overall morbidity and mortality in breast cancer patients
